Description: MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate includes AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.
Home Page: minktherapeutics.com
INKT Technical Analysis
149 Fifth Avenue
New York,
NY
10010
United States
Phone:
212 994 8250
Officers
| Name | Title |
|---|---|
| Dr. Garo H. Armen Ph.D. | Exec. Chairman |
| Dr. Jennifer S. Buell Ph.D. | Pres, CEO & Director |
| Dr. Marcus Antonius van Dijk Ph.D. | Chief Scientific Officer |
| Ms. Christine M. Klaskin | Treasurer |
| Mr. Patrick N. Jordan M.B.A. | VP of Bus. Operations |
| Ms. Kimberly Ha | Head of Investor Relations |
| Ms. Heather Boussios | Gen. Counsel & Chief Compliance Officer |
| Joy Zhou Ph.D. | VP & Head of CMC |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 11.5018 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2021-10-15 |
| Fiscal Year End: | December |
| Full Time Employees: | 33 |